Can lorazepam (Ativan) be used safely during pregnancy?

Lorazepam (Ativan) Should Be Avoided During Pregnancy

Lorazepam should not be used during pregnancy due to significant risks of miscarriage, neonatal sedation and withdrawal syndrome, and potential congenital malformations, with no clear evidence that benefits outweigh these harms. The FDA drug label explicitly warns about these risks and states that use during pregnancy is not recommended 1.

Key Risks Documented

Miscarriage Risk

The most compelling recent evidence demonstrates a substantial increase in miscarriage risk:

• A 2024 nationwide case-time-control study found a 69% increased risk of miscarriage (OR 1.69; 95% CI 1.52-1.87) with benzodiazepine use during pregnancy 2
• Lorazepam specifically showed an OR of 1.39-2.52 depending on the analysis, indicating it is not exempt from this class effect 2
• A 2026 meta-analysis confirmed this association (pooled OR 1.68; 95% CI 1.48-1.90), with evidence of dose-response relationship—higher doses confer greater risk 3
• The association remained significant even after adjusting for publication bias and unmeasured confounding 3, 2

Neonatal Complications

The FDA label clearly documents that benzodiazepines cross the placenta and cause:

• Neonatal sedation: respiratory depression, hypotonia, lethargy, and feeding difficulties 1
• Neonatal withdrawal syndrome: hyperreflexia, irritability, restlessness, tremors, inconsolable crying when used late in pregnancy 1
• These effects require monitoring and management of exposed neonates 1

Potential Congenital Malformations

• One registry study identified a specific association between lorazepam and anal atresia (OR 6.2; 95% CI 2.4-15.7) 4
• While the FDA states that observational studies "do not report a clear association with benzodiazepines and major birth defects," this does not establish safety—it reflects conflicting evidence 1
• The FDA recommends level 2 ultrasonography if exposure occurs to rule out visible malformations 5

Clinical Management Algorithm

If Patient Is Currently Taking Lorazepam and Planning Pregnancy:

1. Taper gradually before conception to avoid abrupt discontinuation syndrome (rebound anxiety, seizures in high-dose users) 6
2. Transition to non-pharmacological interventions: cognitive behavioral therapy, mindfulness-based stress reduction
3. If pharmacotherapy is absolutely necessary, consider alternatives with better pregnancy safety profiles (though all psychotropics require careful risk-benefit analysis)

If Patient Discovers Pregnancy While Taking Lorazepam:

1. Do NOT stop abruptly—this can cause dangerous withdrawal 6
2. Initiate gradual taper under close supervision
3. Arrange level 2 ultrasonography at 18-20 weeks to assess for structural anomalies 5
4. Prepare neonatal team for potential sedation/withdrawal monitoring at delivery 1

Special Considerations:

• Concurrent opioid use is absolutely contraindicated due to synergistic respiratory depression risk 1
• The guideline notes that methadone may be more appropriate than buprenorphine when benzodiazepines are being used concurrently in opioid use disorder, though ideally benzodiazepines should be discontinued 7
• Lorazepam contains benzyl alcohol, which poses additional toxicity risks in preterm infants (hypotension, metabolic acidosis, kernicterus) 1

Common Pitfalls to Avoid

1. Do not reassure patients that "a little exposure won't hurt"—the dose-response data show even lower doses increase risk 3
2. Do not abruptly discontinue upon pregnancy confirmation—taper gradually to prevent withdrawal 6
3. Do not assume the risk is only theoretical—multiple large-scale studies now confirm measurable harm 3, 2
4. Do not prescribe for labor or cesarean section—the FDA explicitly states "such use is not recommended" due to insufficient safety data 1

Breastfeeding Considerations

If a patient requires lorazepam postpartum, the FDA warns that lorazepam is present in breast milk and causes sedation, poor feeding, and poor weight gain in infants 1. Infants must be monitored closely if breastfeeding continues 1.

The evidence is clear and consistent: lorazepam poses documented risks to pregnancy outcomes and neonatal health that outweigh potential benefits in the vast majority of clinical scenarios 1, 3, 2.